GLP-1 Weight-Loss Medications Show Varied Effects on Body Contouring Surgery Risks
A study published in Plastic and Reconstructive Surgery® suggests that GLP-1 weight-loss medications may have varied effects on complication risks for patients undergoing body contouring surgery to remove excess abdominal skin after significant weight loss. The research indicates that while GLP-1 receptor agonist (GLP1ra) medications appear broadly safe perioperatively, they might subtly influence wound healing. This finding is particularly relevant as GLP-1 medications are increasingly used in patients undergoing body contouring procedures like panniculectomy, which addresses loose skin and fat from the lower abdomen.
Understanding the Study's Approach
Led by Zachary Andrew Koenig, MD, of West Virginia University School of Medicine, the study analyzed outcomes from 373 patients who underwent panniculectomy between 2013 and 2023. Approximately 21.7% of these patients were taking GLP-1 medications before surgery, a rate that has notably increased in recent years. Patients undergoing bariatric or hernia surgery were excluded to focus specifically on the effects of GLP-1 drugs.
Key Findings on Complication Risks
Patients on GLP-1 medications were more likely to have type 2 diabetes, high blood pressure, and chronic obstructive pulmonary disease, though their body mass index was not significantly different from non-GLP-1 users.
GLP-1 users had a significantly higher risk of delayed wound healing, observed in 18.5% of this group compared to just 7.5% in the non-GLP-1 group.
Conversely, GLP-1 users showed a lower rate of seroma (fluid build-up under the wound) at 4.9% versus 14.0% in non-GLP-1 users.
Other complications, including surgical wound reopening (dehiscence), infection, and rehospitalization rates, were similar between both groups.
Conclusion and Future Recommendations
The study highlights a complex relationship between GLP-1 treatment and healing following panniculectomy.
While GLP1ra therapy does not appear to increase major surgical risk, it may impact specific aspects of healing that require proactive management.
The researchers emphasize the need for continued research and the development of formal guidelines concerning GLP-1 medications in the context of plastic surgery.